spacer
home > > winter 2020 > paving the way
PUBLICATIONS


Paving the Way



Over the last few decades, there have been more new drug launches than ever before, with a recordbreaking 59 approvals by the FDA in 2018 (1). This has, in part, been fueled by the shift to treatments customised for rare diseases and personalised medicines, which accounted for 42% of all approvals last year (2). The pace of innovation has accelerated as researchers and scientists challenge the frontiers of genomics, microbiology, and diagnostics, contributing to a dramatic rise in the number of trials demanded in the growing life science industry (3).

However, while breakthroughs continue to be made, the path to bring new medicines to market has not shortened. In fact, the drug development process has become increasingly complex, and the pace of trials is slow (4). Finding targeted patient populations and investigators to participate in trials is difficult as sponsor companies compete to collect more and more clinical research data, much of which is difficult and time-consuming to measure (5).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Rik Van Mol is Vice President, Cloud Strategy, at Veeva Systems with over 20 years of experience in both management consulting and cloud software in the life science/pharma sector. Rik’s experience has been built in assisting clients through complex transformation programmes across the life sciences value chain for most of the world’s largest companies. Rik is a recognised thought leader in the industry with deep expertise in architecting, launching, and implementing innovative and industryleading strategies and solutions.
Print this page
Send to a friend
Privacy statement
News and Press Releases

SHL attends the 2020 PDA in virtual fashion

SHL will join the 2020 Parenteral Drug Association’s annual Universe of Pre-Filled Syringes and Injection Devices virtual event with the launch of our virtual experience platform. Visitors can attend the event through the PDA’s online platform that comprises live chat sessions, conference presentations, and company pages.
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement